LAVA Therapeutics signed agreement with CATO SMS to conduct its Phase I/IIa trial with T-cell engager LAVA-051 in hematologic malignancies
NOVEMBER 24, 2020 Utrecht, the Netherlands & Philadelphia, USA and Schiphol, the Netherlands 24 November 2020 – LAVA Therapeutics (“LAVA”) and CATO SMS today announced that CATO SMS is supporting LAVA’s Phase I/IIa open-label trial to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, immunogenicity and antitumor activity of LAVA-051 in patients with relapsed or refractory CD1d-positive chronic […]
BARDA Selects Pharm-Olam to Support Clinical Trial Planning & Execution for up to 5 Years
BARDA selects Pharm-Olam to join its Clinical Studies Network. The IDIQ agreement is for a minimum of two years and a maximum of five years with a total ceiling value of $250 million. Pharm-Olam will provide CRO services for medical countermeasures (MCMs) development. OCTOBER 8, 2020 HOUSTON, Texas, October 8, 2020 – Pharm-Olam, a global […]
Double Bond Pharmaceutical concludes Key Opinion Leader (KOL) meeting, an important milestone for SI-053 Phase 1 clinical study
SEPTEMBER 29, 2020 Uppsala, Sweden, September 28, 2020 – DBP has recently concluded KOL meeting with Professor Dr. Manfred Westphal (Department of neurosurgery, University Hospital Hamburg, Germany) and Professor Dr. Clemens M. F. Dirven (Department of Neurosurgery Erasmus Medical Center, The Netherlands), which has resulted in fine-tuning the Phase 1 clinical plan. This Phase 1 open-label […]
Pharm-Olam Selected as a CRO for Department of Defense Support to Operation Warp Speed Vaccine Trials, Partnering with Geneva Foundation
Pharm-Olam selected by U.S. Department of Defense to support Phase III clinical trials of Operation Warp Speed COVID-19 vaccine candidates. SEPTEMBER 23, 2020 HOUSTON, Texas, September 23, 2020 – Pharm-Olam, a global mid-sized clinical research organization (CRO), has been selected by the U.S. Department of Defense (DOD) to build capability at military treatment facilities in […]
CATO SMS Acquires Array Biostatistics
SEPTEMBER 15, 2020 Global Provider Expands Specialized Clinical Research Offering with Enhanced Biostatistical Services CARY, N.C., September 15, 2020 – CATO SMS announced today that it has acquired Wilmington, NC-based Array Biostatistics (Array) to expand its offering of specialized clinical research solutions. The company plans to invest in growing Array and its highly regarded biostatistical capabilities. Both Array and […]
CATO SMS Unveils New Brand
SEPTEMBER 2, 2020 Cary, N.C., September 2, 2020 (Business Wire) – CATO SMS unveiled its new brand today, revealing an updated look and logo capturing the company’s powerful offering following the merger of CATO Research, LLC and Specialized Medical Services-oncology BV (SMS-oncology). Now, as a fully integrated company, CATO SMS leverages 30 years of global experience to […]
Pharm-Olam Positioning for Growth Trajectory
Pharm-Olam positions organization for growth trajectory with announcing change in ownership. JUNE 24, 2020 Houston, June 24, 2020 – Pharm-Olam, a global midsized clinical research organization (CRO), today announced that they completed a change of ownership transaction on Friday June 19, 2020. This transaction provides Pharm-Olam with enhanced financial flexibility and access to additional capital […]
Pharm-Olam Launches New Protocol Optimization Service
Pharm-Olam, LLC is launching Protocol Optimization Services to support the study development needs of their biopharma clients. JUNE 16, 2020 Houston, June 16th, 2020 – Pharm-Olam, LLC, a global, midsized CRO offering full-service clinical development solutions to the pharmaceutical and biotech industry, is launching Protocol Optimization Services to support the study development needs of their […]
Cytovation Announces Dosing of First Patient in its Phase I/II CICILIA Trial Investigating CyPep-1 in Patients with Solid Cancers
MAY 26, 2020 Bergen, Norway, and Schiphol, the Netherlands – Cytovation AS (“Cytovation”), a clinical-stage biotechnology company focused on developing CyPep-1, a next-generation lytic immunotherapy, is pleased to announce that the first patient has today been successfully dosed in its Phase I/II CICILIA clinical trial. The CICILIA trial will investigate CyPep-1 in patients with advanced […]
CATO SMS Signs Agreement with InteRNA to Facilitate Phase I Solid Tumor Trial
MAY 19, 2020 Utrecht and Schiphol, the Netherlands – InteRNA Technologies B.V. (“InteRNA”) and CATO SMS (“CATO SMS”), a full-service regulatory and clinical CRO specialized in oncology, today announced that both organizations signed an agreement in which CATO SMS will conduct the Phase I clinical trial with microRNA mimic INT-1B3 in patients with advanced solid […]